Choi Yunsuk, Jee Hyunseok
School of Kinesiology, Yeungnam University, Gyeongsan, Gyeongbuk, South Korea.
PLoS One. 2025 Jul 22;20(7):e0327947. doi: 10.1371/journal.pone.0327947. eCollection 2025.
Cancer is a leading cause of mortality worldwide, with approximately 19.6 million new cases and 10 million deaths reported in 2020. Exercise interventions have demonstrated positive effects on physical and mental health in cancer patients, yet there is limited evidence on the efficacy of tailored, high-intensity exercise programs designed using genomic data. This protocol outlines a study aimed at integrating genomic analysis and personalized exercise interventions to improve health outcomes and reduce cancer-related risk factors. This study aims to evaluate the feasibility and potential impact of a personalized exercise intervention delivered through the EXESALUS mobile application. The program integrates genomic information to tailor exercise regimens for cancer prevention, muscle strength improvement, and quality-of-life enhancement.
This is a protocol for a 3-month, parallel-group, randomized controlled trial involving 500 participants, including 100 cancer patients undergoing treatment or rehabilitation and 300 non-cancer participants with elevated disease risk. Participants will engage in the EXESALUS program, which includes low-, moderate-, and high-intensity exercise tailored to genomic profiles, supported by exercise counseling and wearable device feedback. Biospecimens (blood, urine, and oral epithelial cells) will be collected at baseline, 6 weeks, and 3 months to assess genomic variations and physiological changes. Primary outcomes include physical performance (SPPB), muscle strength (1RM and peak power), and skeletal muscle mass (DXA). Secondary outcomes will evaluate mental health indicators such as fatigue (FACIT-F), resilience, anxiety, depression, and quality of life.
This study will provide a detailed framework for implementing ICT-based personalized exercise interventions that incorporate genomic analysis. The EXESALUS program is expected to highlight the potential of tailored high-intensity exercise as a preventive and therapeutic strategy for cancer patients and individuals at risk of chronic diseases. The findings of this protocol will contribute to the development of precision medicine approaches for cancer prevention and management, emphasizing the scalability and utility of ICT-based solutions in health promotion.
This study was registered in the Korean Clinical Trials Registry (KCT0010187).
癌症是全球主要的死亡原因之一，2020年报告的新发病例约为1960万例，死亡病例达1000万例。运动干预已证明对癌症患者的身心健康有积极影响，但关于利用基因组数据设计的量身定制的高强度运动计划的疗效证据有限。本方案概述了一项旨在整合基因组分析和个性化运动干预以改善健康结果并降低癌症相关风险因素的研究。本研究旨在评估通过EXESALUS移动应用程序提供的个性化运动干预的可行性和潜在影响。该计划整合基因组信息，为癌症预防、肌肉力量改善和生活质量提升量身定制运动方案。
这是一项为期3个月的平行组随机对照试验方案，涉及500名参与者，其中包括100名正在接受治疗或康复的癌症患者以及300名疾病风险升高的非癌症参与者。参与者将参与EXESALUS计划，该计划包括根据基因组概况量身定制的低、中、高强度运动，并辅以运动咨询和可穿戴设备反馈。将在基线、6周和3个月时收集生物样本（血液、尿液和口腔上皮细胞），以评估基因组变异和生理变化。主要结局包括身体功能（SPPB）、肌肉力量（1RM和峰值功率）和骨骼肌质量（DXA）。次要结局将评估心理健康指标，如疲劳（FACIT-F）、恢复力、焦虑、抑郁和生活质量。
本研究将为实施结合基因组分析的基于信息通信技术的个性化运动干预提供详细框架。EXESALUS计划有望突出量身定制的高强度运动作为癌症患者和慢性病风险个体的预防和治疗策略的潜力。本方案的研究结果将有助于癌症预防和管理的精准医学方法的发展，强调基于信息通信技术的解决方案在健康促进中的可扩展性和实用性。
本研究已在韩国临床试验注册中心（KCT0010187）注册。
